| niraparib versus placebo | |||
| ENGOT-OV16/NOVA non-gBRCA, NCT01847274 | niraparib (300 mg) once daily versus placebo | patients with platinum-sensitive, recurrent ovarian cancer | double-blind |
| ENGOT-OV16/NOVA gBRCA, 2017 NCT01847274 | niraparib (300 mg) once daily as maintenance treatment versus placebo | patients with platinum-sensitive, recurrent ovarian cancer with germline BRCA mutation | double-blind |
| olaparib versus placebo | |||
| SOLO2/ENGOT-Ov21, NCT01874353 | olaparib 300 mg in two 150 mg tablets, twice daily versus placebo | patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation | double-blind international |
| olaparid versus placebo | |||
| Ledermann, 2012 NCT00753545 | olaparib, at a dose of 400 mg twice daily versus placebo | patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer with or without BRCA1 or BRCA2 germline mutations, who had received two or more platinum-based regimens and had had a partial or complete response to their most recent platinum-based regimen | double-blind |
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
